CoChat
Sign Up
Cited by 392Pituitary Gland Disorders and TreatmentsGrowth Hormone and Insulin-like Growth FactorsNeuroendocrine Tumor Research Advances

Mortality in Patients with Pituitary Disease

Sherlock, Mark, Ayuk, John, Tomlinson, Jeremy W., Toogood, Andrew A., Aragon-Alonso, Aurora, Sheppard, Michael C., Bates, Andrew S., Stewart, Paul M.·2010·Endocrine Reviews
DOI 10.1210/er.2009-0033
Open this paper in CoChat — free account

Abstract

Pituitary disease is associated with increased mortality predominantly due to vascular disease. Control of cortisol secretion and GH hypersecretion (and cardiovascular risk factor reduction) is key in the reduction of mortality in patients with Cushing’s disease and acromegaly, retrospectively. For patients with acromegaly, the role of IGF-I is less clear-cut. Confounding pituitary hormone deficiencies such as gonadotropins and particularly ACTH deficiency (with higher doses of hydrocortisone replacement) may have a detrimental effect on outcome in patients with pituitary disease. Pituitary radiotherapy is a further factor that has been associated with increased mortality (particularly cerebrovascular). Although standardized mortality ratios in pituitary disease are falling due to improved treatment, mortality for many conditions are still elevated above that of the general population, and therefore further measures are needed. Craniopharyngioma patients have a particularly increased risk of mortality as a result of the tumor itself and treatment to control tumor growth; this is a key area for future research in order to optimize the outcome for these patients.

Integrity signals

Registry

Crossref · 10.1210/er.2009-0033

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Even in patients with treated adrenal insufficiency, there continues to be significant morbidity and reduced life expectancy.

    “It has become increasingly evident that, even in patients with treated AI, there continues to be significant morbidity and reduced life expectancy.5–7”

    From Adrenal crisis: prevention and management in adult patients (2019) · cites this paper as [5]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Sherlock, M., Ayuk, J., Tomlinson, J. W., Toogood, A. A., Aragon-Alonso, A., Sheppard, M. C., Bates, A. S., & Stewart, P. M.
Affiliations
  • University of Birmingham (GB)
  • Centre for Endocrinology, Diabetes, and Metabolism (M.S., J.A., J.W.T., A.A.T., A.A.-A., M.C.S., P.M.S.), School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TH, United Kingdom;
  • National Health Service (GB)
Corresponding author
Stewart, Paul M.
ORCID
Venue
Endocrine Reviews
Publisher
The Endocrine Society
Published
2010-06-01
Volume
31
Issue
3
Pages
301-342
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
DOI
10.1210/er.2009-0033
OpenAlex
W2022874606
Cited by
392
References
22
Citations by year
2026: 11 · 2025: 14 · 2024: 22 · 2023: 20 · 2022: 32 · 2021: 22 · 2020: 25 · 2019: 17 · 2018: 26 · 2017: 33 · 2016: 25 · 2015: 29 · 2014: 30 · 2013: 33 · 2012: 35
FWCI
3.89
Type
journal article
Language
en
Open access
closed
Locations
  • Endocrine Reviews (publishedVersion)
  • PubMed (publishedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
  • Lenus, The Irish Health Repository (Dr Steevens Hospital Library) (submittedVersion)
Funders
  • Pfizer
  • National Institute for Health and Care Research (NF-SI-0508-10356)
  • Novo Nordisk
  • Ipsen
  • Medical Research Council
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
Keywords
pituitary disorders, mortality, Cushing's disease, acromegaly, vascular disease, growth hormone hypersecretion, insulin-like growth factor I, ACTH deficiency, hydrocortisone replacement, pituitary radiotherapy, cerebrovascular disease, craniopharyngioma, standardized mortality ratio
MeSH terms
Acromegaly, Craniopharyngioma, Female, Humans, Hypopituitarism, Male, Pituitary Diseases, Cohort Studies, Pituitary ACTH Hypersecretion

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review